Clinical Activities on Schedule and Exceeding Expectations
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, responded to investor inquiries in connection with the significant increase in trading and volatility of its common stock over the past few days. The Company knows of no development associated with its clinical activities that would explain the decline in the price of its common stock. In fact, the clinical activities continue to exceed the Company’s expectations and are on schedule.
However, pursuant to previously disclosed judgments against the Company, ACT issued approximately 70 million shares of its stock to certain investors over the past several weeks, and believes that sales by those investors may be impacting the trading in the Company’s stock.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2010. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company's clinical trials will be successful.
CONTACT:
Investors:
CEOcast, Inc.,
James Young, 212-732-4300
Press:
ACT Corporate Communications,
Bill Douglass, 646-450-3615
or:
Russo Partners,
Martina Schwarzkopf, Ph.D., 212-845-4292
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Other Health Communications Public Relations/Investor Relations General Health
MEDIA: